🇺🇸 FDA
Patent

US 8211894

Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

granted A61PA61P1/00

Quick answer

US patent 8211894 (Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists) held by Theravance, Inc. expires Mon Jun 28 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance, Inc.
Grant date
Tue Jul 03 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 28 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61P, A61P1/00